INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company

MDGLMADRIGAL PHARMACEUTICALS, INC.

CIK 0001157601

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 55
Max Insider Score33
Connections9with evidence

MDGL · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$116K
215 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    CAPITOL COUNSEL LLCLDA RR 2026 first quarter · Health issues, MED, Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    BALLARD PARTNERSLDA Q1 2026 first quarter · Pharmacy · Aug 26, 2026
  • ← Lobbied forevidence
    CROSSROADS STRATEGIES, LLCLDA Q2 2026 second quarter · Medicare/Medicaid, Health issues · Aug 26, 2026
  • ← Insider ofevidence
7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL
$273K
505 sh
Sep 9, 2026
Sep 11, 2026
traded Sep 9, 2026
+2d
SEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$196K
362 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

1
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$57K
106 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

1
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$117K
218 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

1
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$86K
160 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$371K
687 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

1
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$199K
368 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$652K
1,202 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$837K
1,539 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$415K
761 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$87K
160 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

1
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$66K
120 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

0
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$32K
60 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$558K
1,040 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$344K
640 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$184K
347 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$69K
131 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$277K
522 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$280K
520 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$196K
368 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$273K
512 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$212K
396 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$345K
644 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

16
LS
Levy Richard SDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise
M$66K
4,000 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

18
HC
Huntsman CaroleChief Commercial Officer
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$167K
340 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

25
HC
Huntsman CaroleChief Commercial Officer
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$282K
570 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

33
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale
SELL$777K
1,577 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

30
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale
SELL$319K
647 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

9
LS
Levy Richard SDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise
M—
4,000 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$88K
166 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$149K
280 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$177K
332 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$79K
148 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$254K
473 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

10
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$22K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

0
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
24.5K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

0
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$3,792
240 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$22K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$110K
200 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

5
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$291K
18.4K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$492K
960 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$493K
960 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$482K
937 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$814K
1,578 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$269K
521 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

19
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.06M
2,044 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$503K
970 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$280K
539 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$229K
440 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$307K
588 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$383K
732 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$700K
1,335 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$782K
1,489 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$480K
913 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$246K
465 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$293K
554 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$136K
256 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$16K
30 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$21K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

Levy Richard S
Director · Jan 26, 2026
  • ← Insider ofevidence
    Huntsman CaroleChief Commercial Officer · Jan 26, 2026
  • ← Insider ofevidence
    Friedman Paul ADirector · Jan 13, 2026
  • ← Insider ofevidence
    Taub RebeccaDirector · Jan 13, 2026
  • ← Insider ofevidence
    Sibold William JohnDirector, President and CEO · Dec 4, 2025

    • Lobbying

    $760K reported · de-duplicated
    2026 Q2 $380K in-house2026 Q1 $380K in-house
    • CAPITOL COUNSEL LLC—2026 Q1 · posted Aug 26, 2026 · Health issues, MED, Medicare/Medicaid
    • CAPITOL COUNSEL LLC$60K2026 Q1 · posted Aug 26, 2026 · Health issues, MED, Medicare/Medicaid
    • CAPITOL COUNSEL LLC$60K2026 Q2 · posted Aug 26, 2026 · Health issues, MED, Medicare/Medicaid
    • CROSSROADS STRATEGIES, LLC$50K2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
    • BALLARD PARTNERS$120K2026 Q2 · posted Aug 26, 2026 · Pharmacy
    • In-house report$380K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues
    • In-house report$380K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues
    • CROSSROADS STRATEGIES, LLC$50K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues
    • BALLARD PARTNERS$120K2026 Q1 · posted Aug 26, 2026 · Pharmacy

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.